Eplontersen Preserves Heart Health in Clinical Trial

A new study shows eplontersen monotherapy helps maintain patient stability in transthyretin amyloidosis with cardiomyopathy.

Updated on Oct. 26, 2026 in Heart Disease

Eplontersen Preserves Heart Health in Clinical Trial

Live Poll

Should medical treatment success be measured by patient quality of life rather than just survival?

Researchers presented findings from the CARDIO-TTRansform trial, demonstrating that eplontersen monotherapy preserves health status in patients with transthyretin amyloidosis with cardiomyopathy over 140 weeks. The study evaluated patients using the Kansas City Cardiomyopathy Questionnaire to track clinical outcomes.

Why it matters

This analysis provides evidence on how eplontersen treatment impacts the long-term health status of patients suffering from transthyretin amyloidosis with cardiomyopathy. Understanding these treatment effects is critical for managing cardiovascular health in this specific patient population.

In a trial of 1,432 patients with a mean age of 76.4 years, those receiving 45 mg of eplontersen monotherapy showed an odds ratio of 1.7 for being alive and stable. These findings compare to baseline KCCQ scores of 72.5 for the treatment group and 72.7 for the placebo group.

The players

Heart Failure Society of America

This professional organization is dedicated to advancing the care and research of heart failure patients through scientific education and advocacy.

The details

The CARDIO-TTRansform trial enrolled a participant group that was 90.6% male, assigning them to monthly subcutaneous doses of either eplontersen or a placebo. Investigators utilized the Kansas City Cardiomyopathy Questionnaire to measure patient health status throughout the multi-year study period.

The CARDIO-TTRansform trial involved 140 weeks of follow-up and assessment.
Results were presented on October 26, 2026, at the Heart Failure Society of America Annual Scientific Meeting.

Health Landscape

This study contributes to the expanding body of research conducted within the CARDIO-TTRansform trial regarding therapeutic interventions for amyloid cardiomyopathy. It highlights a shift toward prioritizing patient-reported health status as a key indicator of treatment efficacy in chronic cardiac conditions.

Patients with transthyretin amyloidosis with cardiomyopathy may see shifts in their long-term treatment planning as evidence for eplontersen monotherapy matures. The results provide clinicians with data on potential stability and quality of life outcomes to discuss during care management.

The takeaway

The data suggest that eplontersen monotherapy plays a significant role in maintaining patient stability and health status over extended periods. Patients should consult with their cardiologists to understand how these clinical trial findings might influence their current treatment regimen.